Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

NCT04170023 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
29
Enrollment
INDUSTRY
Sponsor class

Stopped Did not appropriately control IVH; significantly increased rates of BTH and LDH excursions (LDH excursions is defined by LDH values \> X2ULN) compared to ravulizumab.

Conditions

Interventions

Sponsor

Alexion Pharmaceuticals, Inc.